Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 354

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 354
---
, the TuHURA Board of Directors approved the First Amendment by written consent, and on April 29, 2025, the Kineta Board of Directors approved the First Amendment by written consent. The parties to the Merger Agreement entered into the First Amendment on May 5, 2025. Recommendation of the TuHURA Board of Directors; TuHURA’s Reasons for the Mergers The TuHURA Board of Directors has unanimously determined that the Mergers are in the best interests of TuHURA; has approved and declared advisable the Merger Agreement, the Mergers, the issuance of shares of TuHURA Common Stock in connection with the Mergers, and the reincorporation of TuHURA from Nevada to Delaware. The TuHURA Board of Directors recommends that TuHURA stockholders vote “FOR” the Authorized Share Increase Proposal and vote “FOR” the Delaware Conversion Proposal. In reaching its decision, the TuHURA Board of Directors consulted with TuHURA management, as well as TuHURA’s legal and financial advisors, and considered various information and a number of factors, weighing both perceived benefits of the Mergers as well as potential risks of the Mergers. The following discussion of the information and factors considered by the TuHURA Board of Directors is not intended to be exhaustive. In view of the wide variety of factors considered by the TuHURA Board of Directors in connection with its evaluation of the Mergers, the TuHURA Board of Directors did not consider it practical to, nor did it attempt to, quantify, rank or otherwise assign relative weights to the specific factors that it considered in reaching its decision. In considering the factors described below, individual members of the TuHURA Board of Directors may have given different weight to different factors. The TuHURA Board of Directors considered this information as a whole and considered overall the information and factors to be favorable to, and in support of, its determinations and recommendation. Among the material information and factors favoring the merger and the other transactions contemplated by the Merger Agreement considered by the TuHURA Board of Directors were the following:

| • |     | The TuHURA Board of Directors’ positive view, based on the scientific, regulatory and technical due                                                                                                                                          
 diligence conducted by TuHURA’s management and advisors, of Kineta’s immuno-oncology pipeline including KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors,